murine autologous anti-CD19 CART cells

P2, N=100, Recruiting, Beijing Boren Hospital | Trial completion date: Nov 2022 --> Nov 2024 | Trial primary completion date: May 2022 --> May 2024

Aims : To prolong relapse-free survival, we combined ASCT and another target humanized CAR-T cells to treat r/r B-NHL patients failed to murinized CD19-CAR-T cells therapy with either CD22 or CD20 antigen expression on tumor cell.The safety and efficacy will be evaluated...B-cell aplasia was documented in all cases(7/7,100%) of CD20-CART group and two cases(2/5,40%) of CD22-CART group during the follow-up... CRS is manageable and has no influence on hematopoiesis reconstitution.With current protocol, complication was mild and encouraging disease control was found. ASCT combined with another target humanized CAR-T therapy is a safe and effective salvage strategy for r/r B-NHL after failure of murinized CD19-CAR-T. Long-term follow-up is needed.

All patients accepted fludarabine and/or cyclophosphamide before cell infusion. Conclusion The salvage treatment of humanized CD19-CART cells resulted in a 67% CR in CD19-positive relapsed B-ALL patients who had a prior murinized CD19-CART therapy, and transplantation followed-by hCD19-CART allowed 90% CR patients to obtain a remission of 2.4-22 months. The prognosis of NR patients was still poor.